(CercleFinance.com) – Transgene fell very slightly on the stock market on Monday after taking stock of its activities and its financial situation at the end of the third quarter.
In its press release, the biotechnology company indicates that it had cash, cash equivalents and other current financial assets representing 36.3 million as of September 30, compared to 49.6 million euros at the end of 2021. .
This amount ensures it has a cash horizon until the end of 2023, specifies the company.
Over the first nine months of the year, its cash consumption amounted to 13.3 million euros, compared to 18.7 million euros for the same period of 2021.
The specialist in cancer immunotherapies based on viral vectors specifies that its operating income amounted to 8.4 million euros, mainly from its collaboration agreement with AstraZeneca, compared to 6.8 million euros in 2021.
The title fell back by 0.4% on Monday on the Paris Stock Exchange following this publication.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
